The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment
- Conditions
- Herpes SimplexHIV Infections
- Registration Number
- NCT00002144
- Lead Sponsor
- Astra USA
- Brief Summary
PRIMARY: To evaluate the clinical activity of foscarnet cream on the index lesion of mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients previously unresponsive to acyclovir treatment.
SECONDARY: To evaluate the clinical activity and virologic activity of foscarnet cream on all treated lesions in this patient population. To evaluate the local tolerance and side effects of treatment with foscarnet cream in this patient population.
- Detailed Description
Patients receive topical applications of one percent foscarnet cream five times daily for up to 6 weeks; those who show no evidence of epithelialization of the index lesion after 3 or more weeks are removed from study and offered intravenous foscarnet. Patients who show a good response to topical foscarnet cream at the end of 6 weeks may continue receiving treatment at the discretion of the investigator.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
George Washington Univ Med Ctr
🇺🇸Washington, District of Columbia, United States
CARE Ctr / UCLA Med Ctr
🇺🇸Los Angeles, California, United States
Bellevue Hosp Ctr
🇺🇸New York, New York, United States
South Miami Hosp
🇺🇸Miami, Florida, United States
Dr Thomas Klein
🇺🇸Chicago, Illinois, United States
Milwaukee County Med Complex
🇺🇸Milwaukee, Wisconsin, United States
Univ Hosps of Cleveland
🇺🇸Cleveland, Ohio, United States
Roger Williams Med Ctr
🇺🇸Providence, Rhode Island, United States